Research Resource for Human Organs and Tissues (U42)

人体器官和组织研究资源 (U42)

• 批准号: 10628539
• 负责人: Thomas J Bell
• 金额: $ 27.03万
• 依托单位: NATIONAL DISEASE RESEARCH INTERCHANGE
• 依托单位国家: 美国
• 财政年份: 1989
• 资助国家: 美国
• 起止时间: 1989-01-09 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10628539
• 关键词: AIDS prevention; Acquired Immunodeficiency Syndrome; Address; Adherence; Administrative Supplement; Aliquot; Authorization documentation; Autopsy; Award; Biological Models; Biomedical Research; CD4 Lymphocyte Count; Cause of Death; Clinic; Collection; Communities; Complex; Data; Development; Disease; Eligibility Determination; Experimental Models; Freezing; Functional disorder; Funding; Generations; Goals; Grant; HIV; HIV Seropositivity; Human; Human Resources; Laboratories; Lead; Medical History; Methodology; Methods; National Institute of Allergy and Infectious Disease; Organ; Parents; Patients; Pharmaceutical Preparations; Play; Principal Investigator; Privatization; Procedures; Process; Protocols documentation; Provider; Publications; Recovery; Reproducibility; Research; Research Personnel; Resources; Scientific Advances and Accomplishments; Scientist; Services; Site; Source; Specialist; Standardization; Techniques; Therapeutic; Tissue Preservation; Tissues; United States National Institutes of Health; Viral; Viral Load result; antiretroviral therapy; base; cohort; comorbidity; effective therapy; human tissue; improved; invention; preservation; programs; screening; translational study

Program Director/Principal Investigator (Last, First, Middle): Bell, Thomas, J. PROJECT TITLE: HTORR/ NIAID High Priority HIV Human Biospecimen Recovery Program PROJECT SUMMARY The development of effective treatments or cures for a wide range of diseases requires translational studies that are directly relevant to human pathophysiology. The use of human biospecimens plays a key role in accelerating scientific discoveries in HIV research by providing scientists with a direct experimental model system to advance understanding of HIV prevention, cure, co-morbidities, and therapeutic strategies. To address several complex issues facing HIV research, including viral persistence, latency and reactivation as well as optimizing preservation methods for human tissues, investigators require access to a unique resource that could provide rigorous and uniform collection of human biospecimens from defined cohorts of HIV positive donors to yield consistent and reproducible experimental results for inventive and groundbreaking studies. As a leading human tissue provider for the biomedical research community, the National Disease Research Interchange (NDRI) is a 501(c)(3), not-for-profit organization that remains at the forefront of coordinating biospecimen procurement to match the needs of advancing scientific experimental methodologies, enabling cutting-edge research. For over 30 years, NDRI has received NIH funding for the parent award to this administrative supplement, the Human Tissue and Organs for Research Resource (HTORR) U42 Grant Number: U42OD011158. To address larger scale and more complex projects in the field of HIV research that are beyond the scope of HTORR, NDRI is expanding its capabilities for the biospecimen collection to align with broader unmet or under represented needs in the field of HIV research. Our current Program Year (PY) 2 efforts include providing rigorous, large scale, uniform collection of human biospecimens from highly defined cohorts of HIV+ donors to optimize tissue preservation methods for HIV studies and to study viral persistence, latency and reactivation. The goal of our PY3 proposal is to continue developing and implementing a large-scale biospecimen collection program to provide ongoing support for high priority HIV studies for NIAID. To accomplish this goal, NDRI will: 1) lead the development of large scale (>120 aliquots per donor) and complex (~30 tissue types per donor) recovery projects, 2) identify and authorize HIV+ donors from both NDRI’s TSS and NIAID’s HIV+ donor referrals, 3) collect relevant HIV+ donor data, 4) coordinate standardized biospecimen procurement, processing, and preservation, and 5) distribute all biospecimens to Dr. Lane’s laboratory. In doing so, the biospecimen collection and preservation methods will be optimized to support the generation of high-quality, reproducible data for scientific review and publication. RELEVANCE Improving treatment for HIV infected patients or finding a cure requires access to high-quality human biospecimens that are suitable for analysis using the most challenging experimental techniques. This approach provides scientists with a direct experimental model system to advance understanding of HIV prevention, cure, co-morbidities, and therapeutic strategies. The overall objective of our Program Year 3 proposal is to continue developing and implementing a highly specialized, ongoing human biospecimen collection program for NIAID’s HIV research initiatives. OMB No. 0925-0001/0002 (Rev. 03/2020 Approved Through 02/28/2023) Page Continuation Format Page

计划主任/首席研究员（最后，第一，中间）：贝尔，托马斯，J。 项目名称：HTORR/ NIAID高优先级HIV人类生物循环恢复计划 项目摘要 开发各种疾病的有效疗法或治疗方法需要翻译研究 与人类病理生理学直接相关。人类生物测量的使用在加速方面起着关键作用 艾滋病毒研究中的科学发现通过为科学家提供直接的实验模型系统来推进 了解艾滋病毒预防，治愈，合并症和治疗策略。解决几个复合物 艾滋病毒研究面临的问题，包括病毒持久性，潜伏期和重新激活以及优化 人类组织的保存方法，调查人员需要获取可以提供的独特资源 从定义的艾滋病毒阳性供体中，严格而统一的人类生物测量收集以产生 一致且可再现的实验结果，用于发明和开创性研究。作为领先的人 生物医学研究界的组织提供商，国家疾病研究互换（NDRI）是 501（c）（3），非营利组织，该组织仍然处于协调生物环境采购的最前沿 符合推进科学实验方法的需求，从而实现尖端研究。为了结束 30年，NDRI已获得该行政补充的父母奖的NIH资金，即人类 研究资源（HTORR）的组织和器官U42赠款编号：U42OD011158。解决较大的问题 艾滋病毒研究领域的规模和更复杂的项目超出了HTORR的范围，NDRI是 扩大其生物循环收集功能，以与更广泛的未满足或在代表性的需求下保持一致 在艾滋病毒研究领域。我们当前的计划年度（PY）2的工作包括提供严格的大规模， 来自高度定义的HIV+供体的人类生物测量的均匀收集，以优化组织 HIV研究的保存方法和研究病毒持久性，潜伏期和重新激活。我们的目标 PY3提案将继续开发和实施大规模的生物循环收集计划 为NIAID提供了持续支持的高优先型艾滋病毒研究。为了实现这一目标，NDRI将：1）领导 大规模开发（每个捐赠者> 120个等分试样）和复合物（每个捐赠者的组织类型）恢复 项目2）从NDRI的TSS和NIAID的艾滋病毒+供体推荐中识别并授权艾滋病毒+捐助者，3） 收集相关的艾滋病毒+供体数据，4）协调标准化的生物循环采购，处理和 保存和5）将所有生物测量分发给莱恩博士的实验室。这样，生物循环系列 并将优化保存方法，以支持生成高质量的可再现数据 科学评论和出版。 关联 改善艾滋病毒感染患者或找到治愈的治疗需要获得高质量的人类 适合使用最挑战的实验技术分析的生物测量。这种方法 为科学家提供直接的实验模型系统，以提高人们对艾滋病毒预防，治愈的了解 合并症和治疗策略。我们计划第三年提案的总体目标是继续 为NIAID开发和实施一项高度专业化的人类生物循环收集计划 艾滋病毒研究计划。 OMB No. 0925-0001/0002（Rev. 03/2020通过02/28/2023批准）页面延续格式页面